Goodwin Procter LLP advised iTeos Therapeutics, Inc. on the deal. iTeos Therapeutics, Inc. (Nasdaq: ITOS) closed its initial public offering of 10,586,316 shares of common stock…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
